PMID- 33970759
OWN - NLM
STAT- MEDLINE
DCOM- 20221118
LR  - 20221118
IS  - 1744-5078 (Electronic)
IS  - 0927-3948 (Linking)
VI  - 30
IP  - 6
DP  - 2022 Aug
TI  - Risk of Ophthalmic Adverse Events in Patients Treated with Immune Checkpoint 
      Inhibitor Regimens: A Systematic Review and Meta-analysis.
PG  - 1449-1459
LID - 10.1080/09273948.2021.1890133 [doi]
AB  - BACKGROUND: Immune checkpoint inhibitors (ICIs) -induced adverse events (AEs) 
      have been reported affecting almost all human organs. However, studies about 
      ocular AEs are few. A meta-analysis was performed to evaluate the risks of 
      ICI-related ophthalmic AEs compare to chemotherapy.Methods: Eligible studies were 
      selected from phase II/III randomized controlled trials investigating ICIs. The 
      data were analyzed by R software and Stata. RESULTS: Odds ratio of 
      treatment-related AE (trAEs) and nonspecific ophthalmic trAEs (NS-trAEs) were 
      lower for PD-1/PD-L1 inhibitors than chemotherapy (OR 0.44, p < .05; OR 0.28, p 
      < .001; OR 0.18, p < . 05; OR: 0.18, p < .001respectively). Compared with 
      monotherapy, PD-1 plus CTLA-4 inhibitors increased the risks of immune-related 
      AEs (irAEs) (OR 4.52, p < .01); ICIs plus chemotherapy increased the risks of 
      trAEs and irAEs (OR 2.82, p < .001; OR 3.63, p < .05 respectively). CONCLUSIONS: 
      PD-L1/PD-1 inhibitors had lower risks of trAEs and NS-trAEs than chemotherapy; 
      Compared with monotherapy, combination therapy had higher risks of ophthalmic 
      trAEs and irAEs. ABBREVIATION: PD-1: programmed cell death protein 1; PD-L1: 
      programmed cell death protein ligand 1; CTLA-4: cytotoxic T-lymphocyte-associated 
      protein 4; ICI: immune checkpoint inhibitor; AE: adverse event; trAE: 
      treatment-related adverse event;irAE: immune-related adverse events; NS-trAE: 
      nonspecific ophthalmic treatment-related adverse event; RCT: randomized 
      controlled trials; PFS: progression-free survival; OS: overall survival; ORR: 
      objective response rate; MM: melanoma; NSCLC: non-small cell lung cancer; SCLC: 
      small cell lung cancer; HNSCC: head-neck squamous cell carcinoma; PICOL: patient, 
      intervention, comparison, and outcome; Versus: VS; Chem: chemotherapy; 95%CI: 95% 
      confidence interval; FEM: fixed-effects model; REM: random-effects model; NA: not 
      applicable; MeSH: medical subject heading.
FAU - Hou, Yan-Li
AU  - Hou YL
AUID- ORCID: 0000-0002-6371-6933
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
FAU - Wang, Di-Ya
AU  - Wang DY
AD  - Department of Radiation Oncology, University of California, San Francisco, 
      California, USA.
FAU - Hu, Jie-Xuan
AU  - Hu JX
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Tian, Ru-Yue
AU  - Tian RY
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Wang, Wei
AU  - Wang W
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Su, Qiang
AU  - Su Q
AD  - Department of Oncology, Beijing Friendship Hospital, Capital Medical University, 
      Beijing, China.
FAU - Li, Hongyang
AU  - Li H
AUID- ORCID: 0000-0001-6786-2105
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
AD  - Multidisciplinary Clinic Center of Ocular Vascular Disease, College of Optometry, 
      Capital Medical University, Beijing, China.
FAU - Wang, Yan-Ling
AU  - Wang YL
AD  - Department of Ophthalmology, Beijing Friendship Hospital, Capital Medical 
      University, Beijing, China.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Systematic Review
DEP - 20210510
PL  - England
TA  - Ocul Immunol Inflamm
JT  - Ocular immunology and inflammation
JID - 9312169
RN  - 0 (Programmed Cell Death 1 Receptor)
RN  - 0 (B7-H1 Antigen)
RN  - 0 (Immune Checkpoint Inhibitors)
RN  - 0 (Antineoplastic Agents, Immunological)
SB  - IM
MH  - Humans
MH  - Programmed Cell Death 1 Receptor
MH  - B7-H1 Antigen/therapeutic use
MH  - Immune Checkpoint Inhibitors/adverse effects
MH  - *Carcinoma, Non-Small-Cell Lung/drug therapy
MH  - *Antineoplastic Agents, Immunological/adverse effects
MH  - *Lung Neoplasms/drug therapy
OTO - NOTNLM
OT  - Treatment-related adverse events
OT  - immune checkpoint inhibitors
OT  - immune-related adverse events
OT  - meta-analysis
OT  - ophthalmic
EDAT- 2021/05/11 06:00
MHDA- 2022/11/19 06:00
CRDT- 2021/05/10 17:30
PHST- 2021/05/11 06:00 [pubmed]
PHST- 2022/11/19 06:00 [medline]
PHST- 2021/05/10 17:30 [entrez]
AID - 10.1080/09273948.2021.1890133 [doi]
PST - ppublish
SO  - Ocul Immunol Inflamm. 2022 Aug;30(6):1449-1459. doi: 
      10.1080/09273948.2021.1890133. Epub 2021 May 10.